Argentina Kawasaki Disease Treatment Market Size & Outlook, 2026-2034
Argentina Kawasaki Disease Treatment Market Insights
- As per Reed Intelligence insights, the Argentina Kawasaki Disease Treatment Market stood at USD 17.95 Million in 2025 and is anticipated to grow to USD 35.65 Million by 2034.
- The Argentina market is expected to advance at a CAGR of 7.9% from 2026 through 2034.
- In 2025, Intravenous Immunoglobulin (IVIG) accounted for the highest share of the Treatment Type market size.
- During the forecast period, Aspirin Therapy is set to register the highest growth, making it the most lucrative Treatment Type segment.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2025, Argentina represented 0.85% of the overall global Kawasaki Disease Treatment Market size.
- United States is projected to lead the global Kawasaki Disease Treatment Market size by 2034.
- Across LATAM, Brazil is anticipated to hold the dominant position in market size by 2034.
- Chile is forecasted to expand at the fastest pace in LATAM, attaining USD 20.29 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 17.95 Million |
| Market Size In 2034 | USD 35.65 Million |
| Largest segment | Intravenous Immunoglobulin (IVIG) |
| Units | Revenue in USD Million |
| CAGR | 7.9% (2026-2034) |
| Segmnetation Covered | |
| Treatment Type |
|
| Drug Class |
|
| Route of Administration |
|
| End-Use |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Argentina Kawasaki Disease Treatment Market Treatment Type 2026-2034 (USD Million)
| Treatment Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intravenous Immunoglobulin (IVIG) | XX.x | XX.x | XX.x | 7.48 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Aspirin Therapy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Corticosteroids | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Biologic Therapies | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Argentina Kawasaki Disease Treatment Market Drug Class 2026-2034 (USD Million)
| Drug Class | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immunoglobulins | XX.x | XX.x | XX.x | 8.21 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Anti-inflammatory Drugs | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Biologics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Argentina Kawasaki Disease Treatment Market Route of Administration 2026-2034 (USD Million)
| Route of Administration | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intravenous | XX.x | XX.x | XX.x | 10.54 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Oral | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Argentina Kawasaki Disease Treatment Market End-Use 2026-2034 (USD Million)
| End-Use | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | XX.x | XX.x | XX.x | 9.55 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Specialty Clinics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Ambulatory Surgical Centers | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
